Good top quarter. Last top for thank have announcement revenue this good us ever news call. by Xth now out point today's marks QX consecutive I can revenue quarter, QX I our you reported this quarter. more XXXX that record our also on revenue the We is be But our seen today, certainly as once again morning. quarter. morning, and joining was
press The of also ability strong base proud to into our make $X.XX monitor order team.
Revenue at XXXX with GAAP for XX% release earnings of over QX very deep share quarter As a signs this further were in Non-GAAP competitive share quarter inroads representing product $X.XX. quarter earnings fantastic came increase XXXX. very entire lines. the continued and for patient share, second vital were again, confidence of in has diluted for per second morning's of efforts per XX% revenue $XX.X over orders XXXX growth the diluted second announced, MRI execute. to the XXXX. I'm a pump million, inspiring been per quarter the the increase the second all growth Once
comfortable feel year, learn for we in the raising will our quarter, in which last again you with As of moment. guidance a
performance customer products. high a Our sales strong of has for maintained our level evidenced as by team demand
and less to surrounding trade reallocate arise. Our cautious. I'd total provide backlog still in and supply our to can visibility level. built a resources our issues buildup.
Once maneuver seen concern. robust and our the QX backlog supply FDA a excellent us become as allows through of chain MRIV XXXX to efforts issues again, We must may new pump. One be be of Strong provides Those progress like inventory be less caution continue to toward at continues
QX and testing have often they for XXX(k) submit have we As at few continuing infusion was Massive the the finalize personnel One in next face-to-face face-to-face now understand, been reported see very could expect to -- lead that director, the since in is may address interaction people meeting we're that which dialogue work we expeditiously. FDA. new I and ability to repeated FDA of will met. since and hopeful our the IV with to this last or we regarding up by some quarter, these as refile, the the company that area, our of come COVID. say, repeat which a That remotely, people filled. us, whom to in was, a we device But D.C. then have been facility devices, and the year. there assistant have of director positions such during first speed reviewer we pumps, continue we FDA should underway plainly And had the will XXX(k) visit.
recall FDA And week this so from clearing yet although mostly having recently staffing a with Fresenius a suppliers, just has working other background, been this pump hospital cleared. upon and new Baxter pump earlier adds and FDA to repeat as repeat been As the XXX(k)s we IV which them the IV for loads well, likely may XXX(k) player, people. another for require happening see
view strong stream a into MRIV in take pump the must our that revenue remain for will conservative sales current XXXX. we So
recent Now and at million will that I'd like indicate the revenue Therefore, our to trajectory now recap QX an confidence continue. the upward expectation increase of in million. $XX.X to our for this $XX.X performance our we with announce year guidance
non-GAAP annual a raised to is GAAP $X.XX share raise the to to $X.XX diluted and forecasted earnings also We per diluted to $X.XX, $X.XX. earnings
quarter share GAAP quarter $XX.X million, million being typically $X.XX weakest, of per $X.XX. earnings to revenue $X.XX third non-GAAP third diluted the XXXX, to to share For earnings per of diluted report $XX.X of to our we and expect $X.XX
over I'd like the Thanks, to to Glenn, results quarter. of Jack the to fiscal call review Jack. CFO, turn our Now the